S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Archer Daniels Midland: Dividend Hero With 49 Years Of Increases
"TAKE THAT, CHINA!" USA Gains in EV Battery Arms Race (Ad)
Russia's lower house of parliament endorses treaties for 4 regions of Ukraine to join Russia
Brazil holds historic election with Lula against Bolsonaro
"White Gold" is the New Oil (Ad)
US shift away from coal hits tribal community in New Mexico
Will Fully Autonomous Tractors Make Deere the Tesla of Farming?
"White Gold" is the New Oil (Ad)
Magna International is Your Auto and EV One-Stop Shop Stock
Tesla sales bounce back in Q3 but fall short of estimates
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Archer Daniels Midland: Dividend Hero With 49 Years Of Increases
"TAKE THAT, CHINA!" USA Gains in EV Battery Arms Race (Ad)
Russia's lower house of parliament endorses treaties for 4 regions of Ukraine to join Russia
Brazil holds historic election with Lula against Bolsonaro
"White Gold" is the New Oil (Ad)
US shift away from coal hits tribal community in New Mexico
Will Fully Autonomous Tractors Make Deere the Tesla of Farming?
"White Gold" is the New Oil (Ad)
Magna International is Your Auto and EV One-Stop Shop Stock
Tesla sales bounce back in Q3 but fall short of estimates
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Archer Daniels Midland: Dividend Hero With 49 Years Of Increases
"TAKE THAT, CHINA!" USA Gains in EV Battery Arms Race (Ad)
Russia's lower house of parliament endorses treaties for 4 regions of Ukraine to join Russia
Brazil holds historic election with Lula against Bolsonaro
"White Gold" is the New Oil (Ad)
US shift away from coal hits tribal community in New Mexico
Will Fully Autonomous Tractors Make Deere the Tesla of Farming?
"White Gold" is the New Oil (Ad)
Magna International is Your Auto and EV One-Stop Shop Stock
Tesla sales bounce back in Q3 but fall short of estimates
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Archer Daniels Midland: Dividend Hero With 49 Years Of Increases
"TAKE THAT, CHINA!" USA Gains in EV Battery Arms Race (Ad)
Russia's lower house of parliament endorses treaties for 4 regions of Ukraine to join Russia
Brazil holds historic election with Lula against Bolsonaro
"White Gold" is the New Oil (Ad)
US shift away from coal hits tribal community in New Mexico
Will Fully Autonomous Tractors Make Deere the Tesla of Farming?
"White Gold" is the New Oil (Ad)
Magna International is Your Auto and EV One-Stop Shop Stock
Tesla sales bounce back in Q3 but fall short of estimates
NASDAQ:TRVN

Trevena - TRVN Stock Forecast, Price & News

$0.15
0.00 (-0.91%)
(As of 09/30/2022 09:02 PM ET)
Add
Compare
Today's Range
$0.15
$0.17
50-Day Range
$0.15
$0.27
52-Week Range
$0.15
$1.33
Volume
607,500 shs
Average Volume
1.33 million shs
Market Capitalization
$26.61 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$1.50

Trevena MarketRank™ Forecast

Analyst Rating
N/A
0.00 Rating Score
Upside/​Downside
879.1% Upside
$1.50 Price Target
Short Interest
Healthy
1.97% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.68mentions of Trevena in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.36) to ($0.29) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.55 out of 5 stars

Medical Sector

1026th out of 1,095 stocks

Pharmaceutical Preparations Industry

507th out of 547 stocks

TRVN stock logo

About Trevena (NASDAQ:TRVN) Stock

Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV027 for the treatment of acute lung injury contributing to acute respiratory distress syndrome and abnormal blood clotting in patients with COVID-19; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. The company has a collaboration with Imperial College London to evaluate Trv027 in Covid-19 patients. Trevena, Inc. was incorporated in 2007 and is headquartered in Chesterbrook, Pennsylvania.

Receive TRVN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Trevena and its competitors with MarketBeat's FREE daily newsletter.

TRVN Stock News Headlines

Trevena (NASDAQ:TRVN) Coverage Initiated by Analysts at StockNews.com
What Makes Trevena (TRVN) a New Buy Stock
Trevena (TRVN) Reports Q2 Loss, Lags Revenue Estimates
See More Headlines
Receive TRVN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Trevena and its competitors with MarketBeat's FREE daily newsletter.

TRVN Company Calendar

Last Earnings
8/11/2022
Today
10/03/2022
Next Earnings (Estimated)
11/21/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:TRVN
Fax
N/A
Employees
25
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$1.50
High Stock Price Forecast
$1.50
Low Stock Price Forecast
$1.50
Forecasted Upside/Downside
+879.1%
Consensus Rating
N/A
Rating Score (0-4)
0.00
Research Coverage
0 Analysts

Profitability

Net Income
$-51,590,000.00
Pretax Margin
-29,547.00%

Debt

Sales & Book Value

Annual Sales
$570,000.00
Book Value
$0.39 per share

Miscellaneous

Free Float
167,428,000
Market Cap
$26.61 million
Optionable
Optionable
Beta
1.83

Key Executives

  • Ms. Carrie L. BourdowMs. Carrie L. Bourdow (Age 59)
    Pres, CEO & Director
    Comp: $920.39k
  • Mr. Barry Shin (Age 50)
    Sr. VP & CFO
    Comp: $609.94k
  • Dr. Mark A. Demitrack (Age 64)
    Sr. VP & Chief Medical Officer
    Comp: $641.3k
  • Dr. Howard A. Rockman M.D.
    Scientific Founder, Consultant and Member of Scientific Advisory Board
  • Mr. Joel Solomon
    VP, Head of Legal, Chief Compliance Officer & Corp. Sec.
  • Mr. Michael Catalano
    VP of Marketing
  • Mr. Robert T. Yoder (Age 56)
    Sr. VP, Chief Bus. Officer & Head of Commercial Operations
  • Ms. Patricia M. Drake (Age 56)
    Sr. VP & Chief Commercial Officer













TRVN Stock - Frequently Asked Questions

What is Trevena's stock price forecast for 2022?

0 brokerages have issued 1 year price targets for Trevena's stock. Their TRVN share price forecasts range from $1.50 to $1.50. On average, they anticipate the company's share price to reach $1.50 in the next twelve months. This suggests a possible upside of 879.1% from the stock's current price.
View analysts price targets for TRVN
or view top-rated stocks among Wall Street analysts.

How have TRVN shares performed in 2022?

Trevena's stock was trading at $0.5830 at the start of the year. Since then, TRVN shares have decreased by 73.7% and is now trading at $0.1532.
View the best growth stocks for 2022 here
.

When is Trevena's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 21st 2022.
View our TRVN earnings forecast
.

How were Trevena's earnings last quarter?

Trevena, Inc. (NASDAQ:TRVN) released its quarterly earnings data on Thursday, August, 11th. The biopharmaceutical company reported ($0.09) earnings per share for the quarter, beating the consensus estimate of ($0.11) by $0.02.

What other stocks do shareholders of Trevena own?
What is Trevena's stock symbol?

Trevena trades on the NASDAQ under the ticker symbol "TRVN."

How do I buy shares of Trevena?

Shares of TRVN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Trevena's stock price today?

One share of TRVN stock can currently be purchased for approximately $0.15.

How much money does Trevena make?

Trevena (NASDAQ:TRVN) has a market capitalization of $26.61 million and generates $570,000.00 in revenue each year. The biopharmaceutical company earns $-51,590,000.00 in net income (profit) each year or ($0.35) on an earnings per share basis.

How can I contact Trevena?

Trevena's mailing address is 955 Chesterbrook Boulevard Suite 110, Chesterbrook PA, 19087. The official website for the company is www.trevena.com. The biopharmaceutical company can be reached via phone at (610) 354-8840 or via email at ir@trevena.com.

This page (NASDAQ:TRVN) was last updated on 10/3/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.